These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 29547597)

  • 1. Fixed Combination Antiemetic: A Literature Review on Prevention of Chemotherapy-Induced Nausea and Vomiting Using Netupitant/Palonosetron.
    Clark-Snow RA; Vidall C; Börjeson S; Jahn P
    Clin J Oncol Nurs; 2018 Apr; 22(2):E52-E63. PubMed ID: 29547597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preventing chemotherapy-induced nausea and vomiting with netupitant/palonosetron, the first fixed combination antiemetic: current and future perspective.
    Aapro M; Zhang L; Yennu S; LeBlanc TW; Schwartzberg L
    Future Oncol; 2019 Apr; 15(10):1067-1084. PubMed ID: 30860400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of a fixed combination of netupitant and palonosetron (NEPA) relative to aprepitant plus granisetron (APR + GRAN) for prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a trial-based analysis.
    Botteman M; Nickel K; Corman S; Turini M; Binder G
    Support Care Cancer; 2020 Feb; 28(2):857-866. PubMed ID: 31161436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3-day aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study.
    Chang J; Chen G; Wang D; Wang G; Lu S; Feng J; Li W; Li P; Lanzarotti C; Chessari S; Zhang L
    Cancer Med; 2020 Jul; 9(14):5134-5142. PubMed ID: 32472742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Netupitant-palonosetron (NEPA) for Preventing Chemotherapy-induced Nausea and Vomiting: From Clinical Trials to Daily Practice.
    Aapro M; Jordan K; Scotté F; Celio L; Karthaus M; Roeland E
    Curr Cancer Drug Targets; 2022; 22(10):806-824. PubMed ID: 35570542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NEPA (netupitant/palonosetron) for the antiemetic prophylaxis of nausea and vomiting induced by chemotherapy (CINV) with Folfirinox and Folfoxiri even during the COVID-19 pandemic: a real-life study.
    De Luca R; Volpe C; Mistretta O; Paci R; Ferrera G; Caputo V; Rosati G; Cicero G
    Eur Rev Med Pharmacol Sci; 2021 Aug; 25(16):5310-5317. PubMed ID: 34486707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Budget impact of netupitant/palonosetron for the prevention of chemotherapy-induced nausea and vomiting.
    Park SH; Binder G; Corman S; Botteman M
    J Med Econ; 2019 Aug; 22(8):840-847. PubMed ID: 31094589
    [No Abstract]   [Full Text] [Related]  

  • 8. NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron.
    Aapro M; Karthaus M; Schwartzberg L; Bondarenko I; Sarosiek T; Oprean C; Cardona-Huerta S; Hansen V; Rossi G; Rizzi G; Borroni ME; Rugo H
    Support Care Cancer; 2017 Apr; 25(4):1127-1135. PubMed ID: 27885469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and Vomiting.
    Hesketh PJ; Aapro M; Jordan K; Schwartzberg L; Bosnjak S; Rugo H
    Biomed Res Int; 2015; 2015():651879. PubMed ID: 26421300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Timing flexibility of oral NEPA, netupitant-palonosetron combination, administration for the prevention of chemotherapy-induced nausea and vomiting (CINV).
    Baron-Hay S; Aapro M; Bernareggi A; Schwartzberg L
    Support Care Cancer; 2019 Apr; 27(4):1309-1317. PubMed ID: 30685793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pro-netupitant/palonosetron (IV) for the treatment of radio-and-chemotherapy-induced nausea and vomiting.
    Celio L; Fabbroni C
    Expert Opin Pharmacother; 2018 Aug; 19(11):1267-1277. PubMed ID: 29985663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy.
    Zelek L; Debourdeau P; Bourgeois H; Wagner JP; Brocard F; Lefeuvre-Plesse C; Chauffert B; Leheurteur M; Bachet JB; Simon H; Mayeur D; Scotté F
    Oncologist; 2021 Oct; 26(10):e1870-e1879. PubMed ID: 34216177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms and latest clinical studies of new NK1 receptor antagonists for chemotherapy-induced nausea and vomiting: Rolapitant and NEPA (netupitant/palonosetron).
    Rojas C; Slusher BS
    Cancer Treat Rev; 2015 Dec; 41(10):904-13. PubMed ID: 26442475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preventing chemotherapy-induced nausea and vomiting in patients with lung cancer: efficacy of NEPA (netupitant-palonosetron), the first combination antiemetic.
    Hesketh PJ; Palmas M; Nicolas P
    Support Care Cancer; 2018 Apr; 26(4):1151-1159. PubMed ID: 29080920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV).
    Navari RM
    Drug Des Devel Ther; 2015; 9():155-61. PubMed ID: 25552904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of an Oral Fixed Combination of Netupitant and Palonosetron (NEPA): Pooled Data From the Phase II/III Clinical Program.
    Aapro M; Hesketh PJ; Jordan K; Gralla RJ; Rossi G; Rizzi G; Palmas M
    Oncologist; 2016 Apr; 21(4):494-502. PubMed ID: 27000465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
    Natale JJ
    Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of NEPA (netupitant/palonosetron) across multiple cycles of chemotherapy in breast cancer patients: A subanalysis from two phase III trials.
    Rugo HS; Rossi G; Rizzi G; Aapro M
    Breast; 2017 Jun; 33():76-82. PubMed ID: 28285236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy.
    Schwartzberg L; Roeland E; Andric Z; Kowalski D; Radic J; Voisin D; Rizzi G; Navari R; Gralla RJ; Karthaus M
    Ann Oncol; 2018 Jul; 29(7):1535-1540. PubMed ID: 29722791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NEPA as antiemetic prophylaxis after failure of 5HT
    Valerio MR; Gebbia V; Borsellino N; Vecchia M; Serretta V; Pardo S; Cipolla C; Galanti D
    J Oncol Pharm Pract; 2021 Apr; 27(3):609-613. PubMed ID: 32507099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.